Did you know?

Corcept has discovered a large portfolio of proprietary compounds, including relacorilant, exicorilant and miricorilant, that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of ...The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol.Corcept's work represents a unique opportunity for a small biopharmaceutical company. The 240-person business has largely flown under the radar since 2012, when it won its first and only Food and ...Mar 6, 2023 · Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer. Sep 30, 2021 · Corcept holds patents covering the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders ... The Corcept name, the Corcept logo, and all related names, logos, product, and service names, designs and slogans, whether appearing in large print or with the trademark symbol, are the trademarks or trade dress of Corcept in the US and other countries. 6.3 Ownership of Feedback.Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...Jul 28, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ... Mar 31, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... Dec 7, 2021 · Corcept conducted the drug-drug interaction study de-scribed in Lee, collecting data on co-administration of mif-epristone with a strong CYP3A inhibitor. Based on that data, Corcept sought and received the ’214 patent . The ’214 patent relates to methods of treating Cushing’s syndrome by co-administering mifepristone and a strong CYP3A in- View the latest Corcept Therapeutics Inc. (CORT) stock price, news, historical charts, analyst ratings and financial information from WSJ.WebCorcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ... Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …WebMENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has commenced a …WebCancer. In cancers that express glucocorticoid receptors (GRs), such as pancreatic, ovarian, and breast cancers, cortisol suppresses programmed cell death (apoptosis). Chemotherapy is intended to provoke cell death. Medications that reduce cortisol’s activation of GR may make chemotherapy more effective. Cortisol modulation may also aid the ...WebCorcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us!Corcept Therapeutics is a company focused on the discovery and development of cortisol modulators in the pharmaceutical industry. The company's main offerings include the development of drugs that modulate the effects of cortisol, which are used to treat a broad range of serious diseases, including endocrine, metabolic, oncologic, and ...Joseph K. Belanoff, MD. Joseph K. Belanoff, M.D. is a co-foundCorcept has discovered a large portfolio of proprietary compound Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.Web Corcept Therapeutics Incorporated is a commercial-stage company, Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).Web Corcept Therapeutics Incorporated is a commercial-stage c

Corcept Therapeutics | 21,335 followers on LinkedIn. Pioneering the discovery and development of cortisol modulators. | Leading the field in the discovery of drugs that modulate the effects of ...Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsCorcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not ...Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)]

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Feb 13, 2023 · Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept …Web…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. 23 Mei 2023 ... Affiliations · Corcept Therapeuti. Possible cause: View the latest Corcept Therapeutics Inc. (CORT) stock price, news, historical c.